Abstracts tagged "treatment"

Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Jaime Calvo-Alén¹, Carmela Baamonde², Ignacio Villa¹, Víctor Martínez-Taboada³, Mario Agudo⁴ and Juan Gómez-Gerique⁵, ¹Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ²Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
Abstract Number: 2381 • 2013 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study
Chantal Tasset, Pille Harrison, Annegret Van der Aa, Luc Meuleners, Frédéric Vanhoutte and Gerben van 't Klooster, Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an oral, selective inhibitor of Janus kinase 1 (JAK1). JAKs signal for cytokines and growth factors, including those involved in rheumatoid arthritis…
Abstract Number: 1793 • 2013 ACR/ARHP Annual Meeting
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Michael Weinblatt¹, Mark C. Genovese², Meilien Ho³, Sally Hollis³, Krystyna Rosiak-Jedrychowicz⁴, Arthur Kavanaugh⁵, David Millson³, Gustavo Leon⁶, Millie Wang³ and Désiréé van der Heijde⁷, ¹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ³AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁴Przychodnia Neuromedyka, Zyrardów, Poland, ⁵University of California, San Diego, La Jolla, CA, ⁶Instituto de Ginecología y Reproducción-Cirugía Mínimamente Invasiva, Surco, Peru, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 52-wk study (NCT01197521) compared Fosta vs placebo (PBO) + methotrexate (MTX) in patients (pts) with active…
Abstract Number: 473 • 2013 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety Of Infliximab In The Treatment Of Rheumatoid Arthritis Over 5 Years: The Canadian Experience
Denis Choquette¹, William Bensen², Andrew Chow³, John T. Kelsall⁴, Maqbool K. Sheriff⁵, Jude F. Rodrigues⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, May Shawi⁸, Francois Nantel⁹, Susan M. Otawa¹⁰ and Allen J. Lehman¹⁰, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁵Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada, ⁹Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Efficacy and safety of anti-TNF in rheumatoid arthritis (RA) management has been demonstrated in numerous controlled clinical trials. Longitudinal observational studies assessing the…
Abstract Number: 2351 • 2013 ACR/ARHP Annual Meeting
Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Ronald F. van Vollenhoven¹, Andrea Rubbert-Roth², Anthony Sebba³, Benjamin Porter-Brown⁴, Lucy Rowell⁵, Pavel Napalkov⁶ and Devi Smart⁵, ¹Karolinska Institute, Stockholm, Sweden, ²Med Clinic I, University of Cologne, koln, Germany, ³University of South Florida, Tampa, FL, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁵Roche, Welwyn Garden City, United Kingdom, ⁶Epidemiology, Genentech, South San Francisco, CA
Background/Purpose: Malignancy is a potential risk of immunomodulatory treatments and may be increased in patients (pts) with rheumatoid arthritis (RA). The risk of malignancy was…
Abstract Number: 1439 • 2013 ACR/ARHP Annual Meeting
Safety, Pharmacokinetics, and Pharmacodynamics Of SAN-300, a Novel Monoclonal Antibody Against Very Late Antigen-1: Results Of a Phase 1 Study In Healthy Volunteers and Patients With Active Rheumatoid Arthritis
Charles Inderjeeth¹, Andrew Redfern¹, Michael Huang², Yun Hardiman², Theresa Grant², Lawrence C. Fritz², David Fuller³, David Haughey⁴ and Mark C. Totoritis², ¹Linear Clinical Research Ltd, Perth, Australia, ²Santarus, Inc., San Diego, CA, ³INC Research, Inc., New South Wales, Australia, ⁴ICON Development Solutions, Whitesboro, NY
Background/Purpose: Very late antigen-1 (VLA-1; α1β1 integrin), a cell adhesion molecule expressed on activated lymphocytes and monocytes/macrophages, binds extracellular matrix molecules and facilitates migration, proliferation,…
Abstract Number: 441 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease‑Modifying Anti-Rheumatic Drugs
G. R. Burmester¹, C Charles-Schoeman², J. D. Isaacs³, T. Hendrikx⁴, K. Kwok⁵, S. H. Zwillich⁶ and R. Riese⁶, ¹Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Charité University Medicine Berlin, Berlin, Germany, ²University of California, Los Angeles, CA, ³Newcastle University, Newcastle-upon-Tyne, United Kingdom, ⁴Pfizer BV, Capelle aan den IJssel, Netherlands, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis provides comparative safety data on the incidence…
Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection
Janet van Adelsberg¹, Steven P. Weinstein², Neil Graham³, Tanya Momtahen⁴, Chunpeng Fan⁵ and Stefano Fiore⁶, ¹Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵Biostatistics, Sanofi, Bridgewater, NJ, ⁶Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
Abstract Number: 1454 • 2013 ACR/ARHP Annual Meeting
The Effects Of The Spleen Tyrosine Kinase Inhibitor Fostamatinib On Ambulatory Blood Pressure In Patients With Active Rheumatoid Arthritis – Results Of The Oskira Ambulatory Blood Pressure Monitoring Trial
G Kitas¹, G Abreu², K Jedrychowicz-Rosiak³, J Miller⁴, R Nakov², S Panfilov², J Vencovsky⁵, M Wang⁶, M Weinblatt⁷ and WB White⁸, ¹The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ²AstraZeneca, Molndal, Molndal, Sweden, ³MCBK SC, Grodzisk Mazowiecki, Poland, ⁴S.W. Florida Clinical Research Center, Florida, FL, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶AstraZeneca, Alderley Park, Macclesfield, United Kingdom, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Fostamatinib (Fosta) is a spleen tyrosine kinase (SYK) inhibitor in clinical trials in patients (pts) with rheumatoid arthritis (RA). Previous clinical studies showed blood…
Abstract Number: 442 • 2013 ACR/ARHP Annual Meeting
Tolerability and Non-Serious Adverse Events In Rheumatoid Arthritis Patients Treated With Tofacitinib As Monotherapy Or In Combination Therapy
A. Dikranian¹, K. Soma², R. Riese², D. Gruben² and T. V. Jones³, ¹San Diego Arthritis Medical Clinic, San Diego, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Tolerability remains an ill-defined construct in clinical trials.…
Abstract Number: 2358 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously Administered, Fully Human Monoclonal Antibody Inhibitor Of The IL-6 Receptor Alpha: 12 Week Infection Rates By Level Of Circulating Neutrophils In Rheumatoid Arthritis and Ankylosing Spondylitis
Kevin L. Winthrop¹, Tanya Momtahen², Stefano Fiore³, Steven P. Weinstein⁴, Janet van Adelsberg⁵, Richard Wu⁶ and Neil Graham⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Program Direction, Sanofi, Bridgewater, NJ, ³Clinical Science, Sanofi, Bridgewater, NJ, ⁴Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁵Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁶BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Sarilumab is a human monoclonal antibody directed against the alpha subunit of the IL-6 receptor (IL-6Rα). IL-6 blockade is associated with a reduction in…
Abstract Number: 1418 • 2013 ACR/ARHP Annual Meeting
Effects Of Smoking Status On Response To Treatment With Tofacitinib In Patients With Rheumatoid Arthritis
J. M. Kremer¹, J. D. Greenberg², C. Turesson³, D. Gruben⁴, C. A. Mebus⁴, E. Bananis⁵ and T. Robinson⁶, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ³Lund University, Malmö, Sweden, ⁴Pfizer Inc, Groton, CT, ⁵Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Cigarette smoking is a known risk factor for developing rheumatoid arthritis (RA).1 Several recent observational studies suggest that cigarette smoking may be associated with…
Abstract Number: 443 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Analyses Of Tofacitinib From Pooled Phase 2, Phase 3 and Long-Term Extension Rheumatoid Arthritis Studies: US Compared With Non-US Populations
S. B. Cohen¹, Roy Fleischmann¹, J. M. Kremer², A. Koenig³, K. Kwok⁴, L. Wang⁵, C. a. Mebus⁵, R. Riese⁵ and T. Robinson³, ¹Metroplex Clinical Research Center, Dallas, TX, ²Albany Medical College and The Center for Rheumatology, Albany, NY, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor approved in the US for the treatment of rheumatoid arthritis at 5 mg BID. Phase (P) 3…
Abstract Number: 2331 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Tofacitinib In Older and Younger Patients With Rheumatoid Arthritis
J. R. Curtis¹, H. Schulze-Koops², L Takiya³, C. A. Mebus⁴, K. Terry⁴, R. Chew⁴ and T. V. Jones³, ¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ²University of Munich, Munich, Germany, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The clinical development program for tofacitinib in RA enrolled ˃500…
Abstract Number: 1387 • 2013 ACR/ARHP Annual Meeting
Reversing Vascular Dysfunction In Rheumatoid Arthritis: Peroxisome Proliferator-Activated Receptor Gamma Agonist Therapy Improves Augmentation Index But Not Endothelial Function
Michelle J. Ormseth¹, Aihua Bian², Annette M. Oeser², Andrew Cunningham², Ayumi Shintani², S. Bobo Tanner³ and C. Michael Stein⁴, ¹Rheumatology, Vanderbilt Medical Center, Nashville, TN, ²Vanderbilt Medical Center, Nashville, TN, ³Div of Rheumatology & Allergy, Vanderbilt Medical Center, Nashville, TN, ⁴School of Medicine, Division of Clinical Pharmacology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is associated with insulin resistance and increased cardiovascular (CV) risk. Impaired vascular function, including arterial stiffness and endothelial dysfunction, is associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.